ABSTRACT
Living organisms are commonly exposed to cadmium and other toxic metals. A vast body of research has shown the significant effects of these toxic metals on developmental processes. In order to study the role of toxic metals on early developmental stages of eukaryotes, we explored the effect of cadmium (Cd2+) contaminant on zebrafish. Thus, zebrafish embryos were exposed to 3 mg/L (16.7 µM) Cd2+ for 96 h and imaged every 24 h from the exposure onwards. Hatching rates of the eggs were determined at 72 h, followed by analyses at 96 h for: survival rate, morphometrical factors, and functional parameters of the cardiovascular system. Interestingly enough, significant hatching delays along with smaller cephalic region and some morphological abnormalities were observed in the treatment group. Moreover, substantial changes were noticed in the length of notochord and embryo, absorption of yolk sac with shorter extension, area of swimming bladder, as well as pericardium sac after Cd2+ treatment. Cadmium also caused significant abnormalities in heart physiology which could be the leading cause of mentioned morphological deformities. Herein, our results shine light on systematic acute embryological effects of cadmium in the early development of zebrafish for the first time.
Subject(s)
Abnormalities, Drug-Induced , Abnormalities, Multiple/chemically induced , Cadmium/toxicity , Embryo, Nonmammalian/drug effects , Embryonic Development/drug effects , Teratogens/toxicity , Water Pollutants, Chemical/toxicity , Abnormalities, Drug-Induced/physiopathology , Animals , Cardiac Output/drug effects , Embryo, Nonmammalian/abnormalities , Embryo, Nonmammalian/physiology , Heart Rate/drug effects , Stroke Volume/drug effects , Zebrafish/abnormalities , Zebrafish/physiologyABSTRACT
Thoracolumbar supernumerary ribs (TSRs) are classified as less severe skeletal anomalies in rat developmental toxicity studies, although their incidence is relatively high in rodent studies. To investigate the characteristics of the critical window for chemically-induced TSR, in this study, rats were administered 5-fluorocytocine (5-FC) or sodium salicylate (SAL) at one of three time periods on gestational day (GD) 9, early morning (7:00 am), midday (12:00 pm to 1:00 pm), or late afternoon (4:00 pm or 7:00 pm). The incidence of TSR and other anomalies were assessed in GD20 fetuses. A single treatment with both chemicals on GD9-induced TSR, with the incidence highest when administered at 7:00 Am, decreasing gradually when administered later. This trajectory was clearer in rats treated with 5-FC than with SAL. The critical period of TSR induction is shorter in rats administered 5-FC than SAL. The characteristics of the critical window may cause variability in the incidence of TSR observed in developmental toxicity studies.
Subject(s)
Abnormalities, Drug-Induced/physiopathology , Fetus/physiopathology , Musculoskeletal Abnormalities/physiopathology , Ribs/physiopathology , Animals , Fetus/drug effects , Flucytosine/toxicity , Humans , Musculoskeletal Abnormalities/chemically induced , Rats , Ribs/growth & development , Sodium Salicylate/toxicity , Teratogens/pharmacology , Teratogens/toxicityABSTRACT
OBJECTIVES: The anticonvulsant valproic acid (VPA) has a known teratogenic effect capable of inducing major congenital malformations and developmental disorders. A comparative teratogenicity study of VPA and its analog valnoctamide (VCD), which is a new generation candidate antiepileptic drug, was carried out using Swiss Vancouver (SWV) mice. METHODS: Pregnant SWV dams were treated with either a single intraperitoneal injection of VPA (1.8 and 2.7 mmol/kg), VCD (1.8 and 2.7 mmol/kg), or vehicle on E8:12 (gestational day:hour). The numbers of implantation and resorption, viable and dead fetuses, and the presence of gross fetal visceral and skeletal abnormalities were determined (E18). Real-time Polymerase chain reaction (RT-PCR) arrays were used to analyze the expression of 84 genes related to the processes of neurogenesis and neural stem cell differentiation. RESULTS: Significant decreases in pregnancy weight gain and the number of live fetuses were observed when VPA was administered at the high dose, whereas the percentage of exencephalic fetuses was significantly increased in VPA treated compared with an equivalent VCD dosage group. There was a dose-related increase in visceral defects in the VPA-exposed fetuses. Missing skull bones and fused vertebrae in fetuses occurred at the high dose of VPA. Three genes (Mtap2, Bmp8b, and Stat3) were significantly upregulated and one (Heyl) was downregulated in samples from VPA-treated dams. CONCLUSIONS: The study demonstrates that the teratogenicity of VPA was significantly greater than that of an equimolar dose of VCD. Four genes (Mtap2, Bmp8b, Stat3, and Heyl) represent candidate target genes for the underlying teratogenic mechanism responsible for VPA-induced malformations.
Subject(s)
Amides/adverse effects , Teratogenesis/drug effects , Valproic Acid/adverse effects , Abnormalities, Drug-Induced/etiology , Abnormalities, Drug-Induced/physiopathology , Amides/pharmacology , Animals , Anticonvulsants/adverse effects , Female , Fetal Death , Fetus/drug effects , Mice , Neural Tube Defects/chemically induced , Pregnancy , Teratogens/metabolism , Teratoma/etiology , Valproic Acid/analogs & derivatives , Valproic Acid/pharmacologyABSTRACT
Fetuses exposed to warfarin during pregnancy are at an increased risk of developing an embryopathy known as fetal warfarin syndrome or warfarin embryopathy. The most consistent anomalies are nasal hypoplasia and stippling of vertebrae or bony epiphyses. Management of pregnant patients on anticoagulation is challenging. Current guidelines suggest the use of warfarin if the therapeutic dose is ≤5 mg/day. We report the case of a newborn with signs of warfarin embryopathy born from a mother anticoagulated with warfarin due to mechanical mitral and aortic heart valves. Warfarin was required at the dose of 5 mg/day and was withheld without medical advice between weeks 8 and 10 with no other anticoagulation. The newborn presented with skeletal abnormalities and a ventricular septal defect that have not required specific treatment during the first year of life. Low-dose warfarin is associated with a lower risk of warfarin-related fetopathy but the risk of embryopathy seems unchanged.
Subject(s)
Abnormalities, Drug-Induced/diagnosis , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Nasal Bone/abnormalities , Pregnancy Complications, Cardiovascular/drug therapy , Warfarin/administration & dosage , Warfarin/adverse effects , Abnormalities, Drug-Induced/physiopathology , Adult , Congenital Abnormalities , Female , Heart Valve Prosthesis , Humans , Infant, Newborn , Male , Nasal Bone/physiopathology , Nasal Cartilages/abnormalities , Pregnancy , Pregnancy Complications, Cardiovascular/physiopathology , Treatment OutcomeABSTRACT
BACKGROUND: In the recent past, many third-generation antiepileptic drugs (AEDs) including Pregabalin (PGB) were launched for the treatment of diverse forms of epilepsy with better efficacy and safety profile than first-and-second-generation AEDs, but their teratogenic safety has not been established so far. OBJECTIVE: The present study has been undertaken to evaluate the reproductive and teratogenic potential (external and skeletal) of a novel and third generation AED, PGB in pregnant albino rats. METHODS: In this study, pregnant subjects were exposed to clinically relevant doses (41, 82 and 123 mg) of PGB from gestation days 6-20, and sacrificed on GD-21, and their fetuses were collected and examined to identify the birth defects and skeletal anomalies. RESULTS: This study revealed that prenatal exposure to PGB induced dose-dependent substantial fetal resorptions, litter size, fetal length and weight; and variety of minor external and internal malformations in fetuses predominant with limbs, tail, eyes, abdomen including hemorrhages, and poor skeletal ossification. CONCLUSION: Thus, PGB was found to be teratogenic in rats at equivalent therapeutic doses, hence precaution should be taken before prescribing PGB to pregnant women with epilepsy.
Subject(s)
Abnormalities, Drug-Induced/etiology , Anticonvulsants/toxicity , Pregabalin/toxicity , Teratogens/toxicity , Abnormalities, Drug-Induced/physiopathology , Animals , Anticonvulsants/administration & dosage , Dose-Response Relationship, Drug , Female , Litter Size/drug effects , Male , Pregabalin/administration & dosage , Pregnancy , RatsABSTRACT
Categorization of fetal external findings in common laboratory animals, intended to make the agreement at Berlin Workshop in 2014 more practical, was proposed by the Terminology Committee of the Japanese Teratology Society at the Workshop in the 55th Japanese Teratology Society Annual Meeting in 2015. In the Workshop, 73 external findings, which had been categorized as "Gray zone" anomalies but not as "Malformation" or "Variation" in the 2014 Berlin Workshop, were discussed and classified as Malformation, "Non-structural abnormality," Variation, and "Not applicable." The proposal was based on the results of a survey conducted in 2014, where 20 facilities (including pharmaceutical, chemical, and pesticide companies and contract laboratories) and 2 selected expert teratologists in Japan were asked for their opinions on the categorization of these findings. Based on the discussion, Japanese Teratology Society members have agreed that 42 out of the 73 findings can be classified as Malformations (38), Non-structural abnormalities (3), Malformations/Non-structural abnormalities (1), and Variations (0), while the remaining 31 findings were recommended to be categorized as Not applicable for fetuses. The details of the classification are shown on the website of the Japanese Teratology Society (http://www.umin.ac.jp/cadb/External.pdf).
Subject(s)
Abnormalities, Drug-Induced/classification , Abnormalities, Drug-Induced/veterinary , Congenital Abnormalities/classification , Congenital Abnormalities/veterinary , Teratogens/toxicity , Terminology as Topic , Abnormalities, Drug-Induced/diagnosis , Abnormalities, Drug-Induced/physiopathology , Animals , Congenital Abnormalities/pathology , Fetus , Humans , Japan , Mice , Rabbits , Rats , Societies, Scientific , Teratology/methods , Toxicology/methodsSubject(s)
Abnormalities, Drug-Induced/genetics , Congenital Abnormalities/genetics , Teratogenesis/drug effects , Teratogens/toxicity , Teratology/education , Abnormalities, Drug-Induced/pathology , Abnormalities, Drug-Induced/physiopathology , Animals , Animals, Genetically Modified , Congenital Abnormalities/pathology , Congenital Abnormalities/physiopathology , Female , History, 21st Century , Humans , Placenta/abnormalities , Placenta/anatomy & histology , Placenta/drug effects , Placenta/metabolism , Pregnancy , Species Specificity , Spermatogenesis/genetics , Teratogenesis/genetics , Teratology/history , WorkforceABSTRACT
The objective of this study was to evaluate the maternal, embryotoxic and teratogenic effects of Caryocar brasiliense pulp oil (OPCB), oil widely used in Brazilian cuisine and traditional medicine. Pregnant Wistar female rats were used in this study for three treatment groups (250, 500 and 1000 mg/kg/day) and a control group. The OPCB was administered orally throughout the period of organogenesis of females (6th until the 15th day of gestation). The pregnant females were gross necropsied on d20, followed by maternal and fetus examination, to evaluate the teratogenicity, reproductive and developmental performance of OPCB. The results showed there was no significant statistical difference in the ponderal evolution of the pregnant females, as well as in the behavioral, hematological, biochemical or histopathological data, indicating the absence of maternal toxicity of the oil. The mean number of corpora lutea, implantation and resorption sites, as well as all calculated reproductive rates, also remained statistically similar between the groups, indicating low embryotoxic effects of the tested plant specie. In fetal examination, external anomalies and skeletal abnormalities were observed in all treated and control groups. The NOAEL for maternal toxicity and embryo/fetal development for the OPCB administered by gavage, was 1000 mg/kg/bw/day.
Subject(s)
Abnormalities, Drug-Induced/embryology , Embryo, Mammalian/drug effects , Ericales/chemistry , Plant Extracts/administration & dosage , Plant Oils/administration & dosage , Abnormalities, Drug-Induced/etiology , Abnormalities, Drug-Induced/physiopathology , Animals , Brazil , Drug Evaluation, Preclinical , Embryonic Development/drug effects , Ericales/toxicity , Female , No-Observed-Adverse-Effect Level , Plant Extracts/chemistry , Plant Extracts/toxicity , Plant Oils/chemistry , Plant Oils/toxicity , Pregnancy , Rats , Rats, Wistar , Reproduction/drug effectsABSTRACT
BACKGROUND: Thalidomide is known to have induced thalidomide embryopathy (TE) in more than 10,000 live-born children worldwide between 1957-1962. AIM: The aim of this study was to investigate the need for orthopaedic surgery and limb orthosis in relation to function and physical independence in middle-aged individuals with TE. METHODS: 13 women/18 men with a mean age of 45.8 (SD 1.1) years were included. Information about limb surgery, the use of orthotic devices, jobs, accommodation, disability adjustments and personal assistants was collected. Physical function was measured by a modified general function score. The time needed for activities of daily living (ADL) was collected. Individuals with proximal focal femoral deficiency, PFFD, and participants in need of home or work adaptations were compared with the rest of the group. RESULT: 31 surgical procedures had been performed in the extremities. Three individuals were in need of personal assistance and seven had disability-adjusted homes. 28 individuals were working and 24 reported participation in exercises. Those with PFFD had significantly lower function score and needed a significantly longer time for ADL in the morning (p = 0.001 and p = 0.032). The group in need of home or work adjustments had significantly lower function score and needed longer time for morning ADL (p = 0.012 and p = 0.009). DISCUSSION: Few orthopaedic procedures had been performed. The TE individuals except the ones with PFFD and those in the need of disability adjustments, were mostly active workers, reported good physical function and participated in exercises, despite limb malformations.
Subject(s)
Abnormalities, Drug-Induced/surgery , Activities of Daily Living , Congenital Abnormalities/surgery , Thalidomide/toxicity , Abnormalities, Drug-Induced/physiopathology , Adult , Congenital Abnormalities/physiopathology , Female , Humans , Male , Middle AgedABSTRACT
Musculoskeletal anatomy is widely known to have components that stray from the norm in the form of variant muscle and tendon presence, absence, origin, insertion, and bifurcation. Although these variant muscles and tendons might be deemed incidental and insignificant findings by most, they can be important contributors to pathologic physiology or, more importantly, an option for effective treatment. In the present case report, we describe a patient with phocomelia and Müllerian abnormalities secondary to in utero thalidomide exposure. The patient had experienced recurrent bilateral foot pain accompanied by numbness, stiffness, swelling, and longstanding pes planus. These symptoms persisted despite conservative treatment with orthotics, steroids, and nonsteroidal anti-inflammatory drugs. Radiographic imaging showed dysmorphic and degenerative changes of the ankle and foot joints. Further investigation with magnetic resonance imaging revealed complex anatomic abnormalities, including the absence of the posterior tibialis and peroneus brevis, lateralization of the peroneus longus, and the presence of a variant anterior compartment muscle. The variant structure was likely a previously described anterior compartment variant, anterior fibulocalcaneus, and might have been a source of the recurrent pain. Also, the absence of the posterior tibialis might have caused the pes planus in the present patient, considering that posterior tibialis tendon dysfunction is the most common cause of acquired pes planus. Although thalidomide infrequently affects the lower extremities, its effects on growth and development were likely the cause of this rare array of anatomic abnormalities and resulting ankle and foot pathologic features.
Subject(s)
Abnormalities, Drug-Induced/diagnostic imaging , Ectromelia/diagnosis , Muscle, Skeletal/abnormalities , Tendons/abnormalities , Thalidomide/adverse effects , Abnormalities, Drug-Induced/physiopathology , Ankle Joint/abnormalities , Ankle Joint/diagnostic imaging , Ectromelia/complications , Female , Follow-Up Studies , Foot Joints/abnormalities , Foot Joints/diagnostic imaging , Humans , Lower Extremity/physiopathology , Magnetic Resonance Imaging/methods , Middle Aged , Muscle, Skeletal/anatomy & histology , Rare Diseases , Risk Assessment , Severity of Illness Index , Tendons/anatomy & histology , Thalidomide/administration & dosageABSTRACT
With respect to hazard classification for developmental toxicity under the CLP Regulation it is important to consider the possible influence of maternal toxicity. The aim of the present review was to characterize to which extent developmental effects could be caused by non-specific maternal toxicity. Such effects would not be relevant for classification. In prenatal developmental toxicity studies, the administration of high doses is given in the guideline. The associated non-specific systemic toxicity often affects the maternal body weight. Therefore, published results of studies in rats and rabbits, where maternal weight gain during gestation was inhibited by restricted feeding, were examined regarding developmental effects. In summary, maternal feed restriction resulted in a reduction of fetal body weight that was sometimes accompanied by delayed ossification in both species. Considering their magnitude these effects could be interpreted as secondary non-specific (i.e. not caused by a developmental toxicant) effects. Based on the limited number of available publications in total no further consequences on prenatal development by maternal feed restriction were observed.
Subject(s)
Animal Nutritional Physiological Phenomena , Fetal Weight/physiology , Maternal Exposure/adverse effects , Toxicity Tests/methods , Weight Loss/physiology , Abnormalities, Drug-Induced/etiology , Abnormalities, Drug-Induced/physiopathology , Animals , Dose-Response Relationship, Drug , Embryonic Development/drug effects , Female , Fetal Weight/drug effects , Male , Pregnancy , Rabbits , Rats , Weight Gain/physiologySubject(s)
Abnormalities, Drug-Induced/diagnosis , Epilepsy/drug therapy , Phenytoin/adverse effects , Respiratory Distress Syndrome, Newborn/diagnosis , Ultrasonography, Prenatal , Abnormalities, Drug-Induced/physiopathology , Abnormalities, Multiple/diagnostic imaging , Abnormalities, Multiple/physiopathology , Administration, Oral , Female , Humans , India , Infant, Newborn , Male , Phenytoin/administration & dosage , Pregnancy , Pregnancy Complications/diagnostic imaging , Rare Diseases , Respiratory Distress Syndrome, Newborn/therapyABSTRACT
BACKGROUND: Between 1957 and 1962 thalidomide was used as a nonaddictive, nonbarbiturate sedative that also was successful in relieving the symptoms of morning sickness in early pregnancy. Infamously, thousands of babies were subsequently born with severe birth defects. The drug is used again, today, to successfully treat leprosy, and tragically, there is a new generation of thalidomide damaged children in Brazil. While the outward damage in babies has been documented, the effects of the damage upon the survivors as they grow up, the lifestyle changes and adaptations required to be made, as well as studies into ageing in survivors, has received little attention and remains understudied. METHODS: A unique multidisciplinary meeting was organized at the University of York bringing together thalidomide survivors, clinicians, scientists, historians, and social scientists to discuss the past, the current and the future implications of thalidomide. RESULTS: There is still much to learn from thalidomide, from its complex history and ongoing impact on peoples' lives today, to understanding its mechanism/s to aid future drug safety, to help identify new drugs retaining clinical benefit without the risk of causing embryopathy. CONCLUSION: For thalidomide survivors, the original impairments caused by the drug are compounded by the consequences of a lifetime of living with a rare disability, and early onset age-related health problems. This has profound implications for their quality of life and need for health and social care services. It is vital that these issues are addressed in research, and in clinical practice if thalidomide survivors are to "age well". Birth Defects Research 109:296-299, 2017. © 2017 Wiley Periodicals, Inc.
Subject(s)
Abnormalities, Drug-Induced/psychology , Aging/drug effects , Hypnotics and Sedatives/adverse effects , Immunosuppressive Agents/adverse effects , Leprostatic Agents/adverse effects , Thalidomide/adverse effects , Abnormalities, Drug-Induced/pathology , Abnormalities, Drug-Induced/physiopathology , Adult , Aging/pathology , Child , Disabled Persons/psychology , Female , Humans , Hypnotics and Sedatives/administration & dosage , Immunosuppressive Agents/administration & dosage , Interdisciplinary Studies , Leprostatic Agents/administration & dosage , Middle Aged , Pharmacovigilance , Pregnancy , Quality of Life/psychology , Thalidomide/administration & dosage , United KingdomABSTRACT
Cannabis sativa preparations are the most consumed illicit drugs for recreational purposes worldwide, and the number of people seeking treatment for cannabis use disorder has dramatically increased in the last decades. Due to the recent decriminalization or legalization of cannabis use in the Western Countries, we may predict that the number of people suffering from cannabis use disorder will increase. Despite the increasing number of cannabis studies over the past two decades, we have gaps of scientific knowledge pertaining to the neurobiological consequences of long-term cannabis use. Moreover, no specific treatments for cannabis use disorders are currently available. In this review, we explore new research that may help fill these gaps. We discuss and provide a solution to the experimental limitation of a lack of rodent models of THC self-administration, and the importance this model can play in understanding the neurobiology of relapse and in providing a biological rationale for potential therapeutic targets. We also focus our attention on glial cells, commenting on recent preclinical evidence suggesting that alterations in microglia and astrocytes might contribute to the detrimental effects associated with cannabis abuse. Finally, due to the worrisome prevalence rates of cannabis use during pregnancy, we highlight the associations between cannabis use disorders during pregnancy and congenital disorders, describing the possible neuronal basis of vulnerability at molecular and circuit level. This article is part of the Special Issue entitled "A New Dawn in Cannabinoid Neurobiology".
Subject(s)
Abnormalities, Drug-Induced/physiopathology , Marijuana Abuse/drug therapy , Marijuana Abuse/physiopathology , Neuroglia/drug effects , Animals , Disease Models, AnimalABSTRACT
BACKGROUND: Hypothesised associations between in utero exposure to selective serotonin reuptake inhibitors (SSRIs) and congenital anomalies, particularly congenital heart defects (CHD), remain controversial. We investigated the putative teratogenicity of SSRI prescription in the 91 days either side of first day of last menstrual period (LMP). METHODS AND FINDINGS: Three population-based EUROCAT congenital anomaly registries- Norway (2004-2010), Wales (2000-2010) and Funen, Denmark (2000-2010)-were linked to the electronic healthcare databases holding prospectively collected prescription information for all pregnancies in the timeframes available. We included 519,117 deliveries, including foetuses terminated for congenital anomalies, with data covering pregnancy and the preceding quarter, including 462,641 with data covering pregnancy and one year either side. For SSRI exposures 91 days either side of LMP, separately and together, odds ratios with 95% confidence intervals (ORs, 95%CI) for all major anomalies were estimated. We also explored: pausing or discontinuing SSRIs preconception, confounding, high dose regimens, and, in Wales, diagnosis of depression. Results were combined in meta-analyses. SSRI prescription 91 days either side of LMP was associated with increased prevalence of severe congenital heart defects (CHD) (as defined by EUROCAT guide 1.3, 2005) (34/12,962 [0.26%] vs. 865/506,155 [0.17%] OR 1.50, 1.06-2.11), and the composite adverse outcome of 'anomaly or stillbirth' (473/12962, 3.65% vs. 15829/506,155, 3.13%, OR 1.13, 1.03-1.24). The increased prevalence of all major anomalies combined did not reach statistical significance (3.09% [400/12,962] vs. 2.67% [13,536/506,155] OR 1.09, 0.99-1.21). Adjusting for socio-economic status left ORs largely unchanged. The prevalence of anomalies and severe CHD was reduced when SSRI prescriptions were stopped or paused preconception, and increased when >1 prescription was recorded, but differences were not statistically significant. The dose-response relationship between severe CHD and SSRI dose (meta-regression OR 1.49, 1.12-1.97) was consistent with SSRI-exposure related risk. Analyses in Wales suggested no associations between anomalies and diagnosed depression. CONCLUSION: The additional absolute risk of teratogenesis associated with SSRIs, if causal, is small. However, the high prevalence of SSRI use augments its public health importance, justifying modifications to preconception care.
Subject(s)
Abnormalities, Drug-Induced/physiopathology , Antidepressive Agents/adverse effects , Heart Defects, Congenital/physiopathology , Pregnancy Complications/epidemiology , Selective Serotonin Reuptake Inhibitors/adverse effects , Abnormalities, Drug-Induced/epidemiology , Adult , Antidepressive Agents/therapeutic use , Databases, Factual , Denmark , Depressive Disorder/complications , Depressive Disorder/drug therapy , Depressive Disorder/epidemiology , Female , Heart Defects, Congenital/chemically induced , Heart Defects, Congenital/epidemiology , Humans , Norway , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/physiopathology , Selective Serotonin Reuptake Inhibitors/therapeutic use , WalesABSTRACT
BACKGROUND: Alterations in cognitive/affective functioning are among the most challenging adverse effects experienced by 80% of patients with metastatic melanoma and metastatic renal cell carcinoma undergoing high-dose interleukin 2 (IL-2) therapy. OBJECTIVE: The purpose of this literature review is to describe what is known about IL-2-induced cognitive/affective symptoms, their prevalence, and level of severity and synthesize findings to determine areas for future research to address symptom management challenges. This review describes the IL-2 patient experience and the pathophysiology leading to these changes. METHODS: An online electronic search using PubMed was performed to identify relevant literature published between 1992 and 2015. Of the original 113 articles, information was extracted from 9 articles regarding cognitive symptoms, affective symptoms, sample size, research design, reliability, and validity. RESULTS: Our review suggests that the trajectories, breadth, and depth of cognitive/affective symptoms have yet to be described. Despite intervention studies designed to address the psychosocial complications of IL-2, an understanding of the level of altered cognitive/affective symptoms experienced by IL-2 patients remains unclear. CONCLUSION: Our literature review reveals a lack of standardization when assessing, reporting, and managing cognitive/affective symptoms. Patients/family members have reported cognitive/affective symptoms to be the most alarming and difficult symptoms, yet these symptoms are not adequately screened for, and patients were not informed about potential changes. IMPLICATIONS FOR PRACTICE: Assessing patients for cognitive/affective alterations is important to reduce anxiety while improving outcomes. Education about the illness trajectory (what to expect during/after treatment) can help care partners/patients set realistic shared expectations and increase coping.
Subject(s)
Abnormalities, Drug-Induced/physiopathology , Affective Symptoms , Cognition , Interleukin-2/adverse effects , Neoplasms/complications , Adult , Aged , Humans , Interleukin-2/pharmacology , Middle Aged , Neoplasms/psychology , PrevalenceABSTRACT
Rabbits may serve as a useful model for predicting the human risk for methanol (MeOH) teratogenicity, which currently is unknown. New Zealand white (NZW) rabbits are resistant to the MeOH-initiated gross morphological anomalies characteristically observed in several strains of mice and rats, but skeletal development has not been assessed. Pregnant rabbits were administered 2 doses of 2g/kg MeOH on gestational day (GD) 7 or 8, and assessed for skeletal abnormalities on GD 29. Variations between treated and control fetuses were observed only in the number of post-lumbar vertebrae, where MeOH-exposed fetuses had fewer ossified vertebrae, which has not been reported for rodents. Furthermore, rabbits did not exhibit the MeOH-initiated skeletal defects characteristically reported for rodent fetuses. These results expand the morphological breadth of the relative species-dependent resistance of rabbits to MeOH teratogenicity compared to rodents, yet reveal a novel skeletal defect or delay in ossification not reported for rodents.
Subject(s)
Abnormalities, Drug-Induced/etiology , Methanol/toxicity , Osteogenesis/drug effects , Spine/drug effects , Teratogens/toxicity , Abnormalities, Drug-Induced/pathology , Abnormalities, Drug-Induced/physiopathology , Animals , Female , Gestational Age , Maternal Exposure , Mice , Models, Animal , Pregnancy , Rabbits , Rats , Risk Assessment , Species Specificity , Spine/abnormalities , Spine/physiopathologyABSTRACT
INTRODUCTION: Drugs teratogenicity has been studied for many years, especially teratogenic effects of antiepileptic drugs, because of the important impact that epilepsy has always had for young women, but data from literature are often conflicting. AREAS COVERED: We have carried out a critical review of all human studies about the antiepileptic drugs teratogenicity. A systematic search was performed in Medline and PubMed up to May 1, 2015. The use of older antiepileptic drugs in pregnancy is associated with an increased risk of fetus malformations; in particular, Valproate can determine neural-tube-like defects; in Phenytoin and Phenobarbital-exposed pregnancies, orofacial clefts, cardiac and genitourinary malformations are the major anomalies described. Spina bifida is the only specific major congenital malformation significantly associated with exposure to Carbamazepine monotherapy Despite the small number of studies on the teratogenic effects of new antiepileptic drugs, the analysis of the literature shows that exposure of the fetus to the new antiepileptic drugs is associated with a lower risk of major congenital malformations compared to the use of older drugs. EXPERT OPINION: Where possible, Valproate should be avoided in women of childbearing potential. Results about the safety of newer antiepileptic drugs require validation and further investigation.
Subject(s)
Anticonvulsants/adverse effects , Epilepsy/drug therapy , Pregnancy Complications/drug therapy , Abnormalities, Drug-Induced/epidemiology , Abnormalities, Drug-Induced/etiology , Abnormalities, Drug-Induced/physiopathology , Animals , Anticonvulsants/administration & dosage , Epilepsy/complications , Female , Humans , Pregnancy , Prenatal Exposure Delayed Effects/etiology , Teratogens/toxicityABSTRACT
BACKGROUND: Thalidomide is a known teratogen and it is estimated that more than ten thousand babies were affected by thalidomide embryopathy (TE), which is characterized mainly by limb defects, but can involve many organs and systems. Most people with TE were only evaluated at birth and it is not well established if thalidomide exposure during embryonic development leads to later effects. We analyzed the clinical history of adults with TE to better understand this gap in the clinical findings of TE. METHODS: Brazilian individuals with TE were invited to answer a clinical questionnaire which considered family history, social information, medical history, and current clinical and psychological health status. A clinical examination was also performed, including on the infant subjects to evaluate congenital anomalies. The characterization of the features was analyzed using descriptive statistics and Chi-square or Fisher's exact test. RESULTS: The congenital anomalies caused by thalidomide were reviewed in 28 Brazilian individuals, and the questionnaire was applied to the 23 adult subjects with TE (aged 19 to 55). Progressive deafness and dental loss were reported. From the comparison of TE individuals with the general Brazilian population, the early onset of cardiovascular diseases (p = 0.009) and a higher frequency of psychological disorders (p = 0.011) were observed. CONCLUSION: Although there is no sufficient evidence that thalidomide exposure caused or worsened the described events, this approach helps to better understand the TE phenotype, improves the clinical diagnosis, and can lead to adequate health support for these individuals.
Subject(s)
Fetal Diseases/chemically induced , Fetal Diseases/physiopathology , Thalidomide/adverse effects , Abnormalities, Drug-Induced/physiopathology , Abnormalities, Multiple/chemically induced , Abnormalities, Multiple/physiopathology , Adolescent , Adult , Brazil , Child, Preschool , Female , Follow-Up Studies , Health Status , Humans , Limb Deformities, Congenital/chemically induced , Limb Deformities, Congenital/physiopathology , Male , Middle Aged , Phenotype , Young AdultABSTRACT
BACKGROUND: In utero exposure to thalidomide causes a wide range of birth defects, including phocomelia, hearing loss and visceral disorders, known as thalidomide embryopathy (TE). Fifty years after the first report of TE, we conducted the first cross-sectional multicenter study to investigate the development of lifestyle-related diseases and identify risk factors for visceral disorders in subjects with TE. METHODS: Seventy-six cases with TE (31 men, 45 women) underwent medical examinations between 2011 and 2014 to determine the types of TE-related anomalies (limbs, auditory organs, or visceral organs) and lifestyle-related diseases present. Logistic multiple regression analyses, adjusted for gender and age, were conducted between TE and lifestyle-related diseases and to evaluate association between block vertebra and gallbladder aplasia. RESULTS: Fatty liver (FL), nonalcoholic FL disease and dyslipidemia were detected in 52.6%, 35.0%, and 23.7% of subjects, respectively, with higher incidences among men. Dyslipidemia was detected in 40.0% of subjects with FL and was significantly associated with FL (odds ratio = 8.86; p = 0.008). Block vertebrae were detected in 44.4% of subjects with gallbladder aplasia, and this association was significant (odds ratio = 9.96; p = 0.006). CONCLUSION: Subjects with TE have also a risk for lifestyle-related disease as well as the general Japanese population. In addition, cervical spine radiography and magnetic resonance imaging are recommended to assess block vertebrae in subjects with TE with gallbladder aplasia who develop shoulder pain.